menu

Mechanisms of Pressure Relief in Glaucoma: Pharmacologic & Surgical Advances

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Mechanisms of Pressure Relief in Glaucoma: Pharmacologic & Surgical Advances for Refractory POAG or Non-Adherence

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

     THIS ACTIVITY IS NO LONGER AVAILABLE FOR CREDIT.

    Glaucoma is the leading cause of irreversible vision loss worldwide and it is expected that the number of people affected by glaucoma will increase dramatically in coming decades due to the aging of the world’s population. Despite advances in ocular imaging and visual field testing, a substantial proportion of patients with glaucoma remain undiagnosed and present late in the course of their disease. At the same time, while several classes of drugs are used to manage patients with glaucoma, significant unmet needs persist in glaucoma care.

    In this CME/CE-certified enduring activity, glaucoma experts will discuss new pharmacologic and surgical advances in primary open-angle glaucoma (POAG) and ocular hypertension. Expert faculty will discuss the unmet clinical needs in glaucoma management and will review recently approved therapies together with those in the pipeline that may influence clinical decision-making, and may result in optimum outcomes for non-compliant patients or those refractory to medical therapy alone. Through discussion of creative clinical case scenarios, faculty will also highlight important treatment strategies for glaucoma that ophthalmologists can readily incorporate into clinical practice. These may include reduced complications with MIGS stents and ocular inserts vs. definitive, invasive trabeculectomy; recommendations for single and two-drug failure, noncompliance, and new delivery systems that allow sustained medication release.

  • Disclosure of Conflicts of Interest

    David S. Friedman, MD, PhD, MPH: Consulting Fees—Allergan, Nidek Ltd; Speaker—Alcon, Allergan
    Steven J. Gedde, MD: Consulting Fees—Alcon, Allergan; Grant Support—Abbott Medical Optics, National Eye Institute, Research to Prevent Blindness
    W. Daniel Stamer, PhD: Consulting Fees—Aerie, Glauconix, Precision Biosciences; Contracted Research—Aerie, Allergan, Inotek, Ironwood, Precision Biosciences

  • Target Audience

    This activity has been designed to meet the educational needs of Physicians, NPs, RNs, and PAs who treat patients with glaucoma.

  • Learning Objectives

    After completing this CME/CE activity, the participant will be able to:

    1. Assess the current healthcare needs of patients with open-angle glaucoma
    2. Interpret the new evidence surrounding the underlying mechanism of glaucoma and the subsequent discovery of new therapies that address deficiencies in the clinical care of glaucoma
    3. Discuss the published findings and the clinical significance of the latest surgical techniques and MIGS devices for glaucoma, including how each may be used to achieve IOP targets for a diverse range of patients

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Educational Partners

    This activity is jointly provided by Postgraduate Institute for Medicine and HealthmattersCME.

     ReachMD Healthcare Image   ReachMD Healthcare Image  

  • Commercial Support

    This activity is supported by independent educational grants from Aerie Pharmaceuticals, Inc., Alcon Pharmaceuticals Ltd., and Bausch & Lomb, Inc.

     

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

     THIS ACTIVITY IS NO LONGER AVAILABLE FOR CREDIT.

    Glaucoma is the leading cause of irreversible vision loss worldwide and it is expected that the number of people affected by glaucoma will increase dramatically in coming decades due to the aging of the world’s population. Despite advances in ocular imaging and visual field testing, a substantial proportion of patients with glaucoma remain undiagnosed and present late in the course of their disease. At the same time, while several classes of drugs are used to manage patients with glaucoma, significant unmet needs persist in glaucoma care.

    In this CME/CE-certified enduring activity, glaucoma experts will discuss new pharmacologic and surgical advances in primary open-angle glaucoma (POAG) and ocular hypertension. Expert faculty will discuss the unmet clinical needs in glaucoma management and will review recently approved therapies together with those in the pipeline that may influence clinical decision-making, and may result in optimum outcomes for non-compliant patients or those refractory to medical therapy alone. Through discussion of creative clinical case scenarios, faculty will also highlight important treatment strategies for glaucoma that ophthalmologists can readily incorporate into clinical practice. These may include reduced complications with MIGS stents and ocular inserts vs. definitive, invasive trabeculectomy; recommendations for single and two-drug failure, noncompliance, and new delivery systems that allow sustained medication release.

  • Disclosure of Conflicts of Interest

    David S. Friedman, MD, PhD, MPH: Consulting Fees—Allergan, Nidek Ltd; Speaker—Alcon, Allergan
    Steven J. Gedde, MD: Consulting Fees—Alcon, Allergan; Grant Support—Abbott Medical Optics, National Eye Institute, Research to Prevent Blindness
    W. Daniel Stamer, PhD: Consulting Fees—Aerie, Glauconix, Precision Biosciences; Contracted Research—Aerie, Allergan, Inotek, Ironwood, Precision Biosciences

  • Target Audience

    This activity has been designed to meet the educational needs of Physicians, NPs, RNs, and PAs who treat patients with glaucoma.

  • Learning Objectives

    After completing this CME/CE activity, the participant will be able to:

    1. Assess the current healthcare needs of patients with open-angle glaucoma
    2. Interpret the new evidence surrounding the underlying mechanism of glaucoma and the subsequent discovery of new therapies that address deficiencies in the clinical care of glaucoma
    3. Discuss the published findings and the clinical significance of the latest surgical techniques and MIGS devices for glaucoma, including how each may be used to achieve IOP targets for a diverse range of patients

  • Disclaimer

    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

  • Educational Partners

    This activity is jointly provided by Postgraduate Institute for Medicine and HealthmattersCME.

     ReachMD Healthcare Image   ReachMD Healthcare Image  

  • Commercial Support

    This activity is supported by independent educational grants from Aerie Pharmaceuticals, Inc., Alcon Pharmaceuticals Ltd., and Bausch & Lomb, Inc.

     

Facebook Comments

Schedule19 Mar 2024